betamethasone valerate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prednisone and prednisolone derivatives	354	2152-44-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: betamethasone valerate bextasol celeston valerate valisone bedermin	Betamethasone valerate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Molecular weight: 476.59 Formula: C27H37FO6 CLOGP: 3.91 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 100.90 ALOGS: -4.85 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

betamethasone valerate
bextasol
celeston valerate
valisone
bedermin

Betamethasone valerate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Molecular weight: 476.59
Formula: C27H37FO6
CLOGP: 3.91
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 100.90
ALOGS: -4.85
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.06 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Sept. 2, 1967	FDA	SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	708.81	18.54	234	10922	24142	63453724
Blepharospasm	225.01	18.54	70	11086	5926	63471940
Taste disorder	172.09	18.54	71	11085	13591	63464275
Psoriasis	168.52	18.54	132	11024	86825	63391041
Chronic sinusitis	152.51	18.54	64	11092	12779	63465087
Epilepsy	134.08	18.54	74	11082	26991	63450875
Paraesthesia oral	121.85	18.54	62	11094	19194	63458672
Procedural pain	115.22	18.54	62	11094	21507	63456359
Drug ineffective	106.19	18.54	411	10745	1044354	62433512
Heart sounds	94.30	18.54	24	11132	972	63476894
Vaginal flatulence	93.03	18.54	31	11125	3262	63474604
Prolonged expiration	92.03	18.54	24	11132	1072	63476794
Proctitis	77.84	18.54	31	11125	5410	63472456
Migraine	74.06	18.54	91	11065	103255	63374611
Female genital tract fistula	71.19	18.54	32	11124	7527	63470339
Acute motor-sensory axonal neuropathy	70.39	18.54	15	11141	274	63477592
Radiculopathy	67.21	18.54	32	11124	8579	63469287
Abdominal pain upper	65.04	18.54	124	11032	206320	63271546
Gastrooesophageal reflux disease	63.38	18.54	81	11075	95558	63382308
Vaginal discharge	62.23	18.54	31	11125	9167	63468699
Depressive symptom	60.88	18.54	24	11132	4078	63473788
Rectal haemorrhage	59.42	18.54	57	11099	48973	63428893
Endocrine ophthalmopathy	57.82	18.54	15	11141	656	63477210
Depressed mood	56.98	18.54	51	11105	40140	63437726
Respiration abnormal	56.74	18.54	26	11130	6391	63471475
Pruritus	56.51	18.54	165	10991	361288	63116578
Dyspepsia	54.68	18.54	78	11078	102118	63375748
Toxic shock syndrome	54.44	18.54	15	11141	827	63477039
Oral candidiasis	53.82	18.54	39	11117	22759	63455107
Appetite disorder	50.49	18.54	25	11131	7296	63470570
Weight decreased	47.74	18.54	131	11025	276667	63201199
Blood pressure inadequately controlled	46.64	18.54	21	11135	4957	63472909
Memory impairment	46.38	18.54	73	11083	104185	63373681
Paraesthesia	45.39	18.54	91	11065	156875	63320991
Lip swelling	45.18	18.54	40	11116	31023	63446843
Eyelid disorder	42.82	18.54	15	11141	1834	63476032
Colitis ulcerative	42.82	18.54	36	11120	26055	63451811
Pain	42.69	18.54	248	10908	740380	62737486
Steroid withdrawal syndrome	41.28	18.54	11	11145	534	63477332
Nasal ulcer	39.60	18.54	15	11141	2289	63475577
Multiple drug therapy	39.39	18.54	17	11139	3629	63474237
Sleep disorder due to a general medical condition	38.60	18.54	25	11131	12163	63465703
Exercise tolerance decreased	38.58	18.54	19	11137	5478	63472388
Angina pectoris	38.40	18.54	36	11120	30042	63447824
Frequent bowel movements	38.26	18.54	32	11124	22990	63454876
Haematochezia	38.07	18.54	47	11109	53497	63424369
Rales	37.66	18.54	25	11131	12672	63465194
Therapeutic product effect incomplete	36.73	18.54	73	11083	124983	63352883
Rash pustular	36.28	18.54	20	11136	7262	63470604
Total cholesterol/HDL ratio abnormal	36.15	18.54	7	11149	77	63477789
Mean cell haemoglobin increased	36.04	18.54	15	11141	2928	63474938
Swelling of eyelid	35.03	18.54	15	11141	3141	63474725
Malaise	34.16	18.54	154	11002	415800	63062066
Wrong technique in device usage process	33.14	18.54	15	11141	3583	63474283
Flank pain	31.90	18.54	25	11131	16385	63461481
Concussion	31.85	18.54	20	11136	9224	63468642
Skin atrophy	31.61	18.54	16	11140	4890	63472976
Skin plaque	31.20	18.54	19	11137	8301	63469565
Dyslipidaemia	30.63	18.54	18	11138	7375	63470491
Hypoaesthesia	30.28	18.54	81	11075	168312	63309554
Death	30.24	18.54	14	11142	374367	63103499
Erythema	30.06	18.54	83	11073	175668	63302198
Weaning failure	29.74	18.54	8	11148	403	63477463
Drug interaction	29.53	18.54	3	11153	229128	63248738
Pyrexia	27.93	18.54	159	10997	470319	63007547
Skin exfoliation	27.73	18.54	36	11120	43066	63434800
Hypotension	27.51	18.54	7	11149	272597	63205269
Colitis	27.35	18.54	38	11118	48490	63429376
Diabetes mellitus inadequate control	27.17	18.54	22	11134	15104	63462762
Narrow anterior chamber angle	26.44	18.54	5	11151	48	63477818
Vulval cancer stage III	25.58	18.54	4	11152	10	63477856
Stevens-Johnson syndrome	24.69	18.54	26	11130	24924	63452942
Vitamin D decreased	22.99	18.54	17	11139	10225	63467641
Rheumatoid arthritis	22.91	18.54	8	11148	253811	63224055
Acute kidney injury	22.61	18.54	9	11147	263406	63214460
Increased bronchial secretion	21.62	18.54	9	11147	1757	63476109
Rash macular	20.76	18.54	23	11133	23341	63454525
Wound necrosis	20.58	18.54	6	11150	406	63477460
Synovial cyst	20.51	18.54	16	11140	10417	63467449
Adrenocorticotropic hormone deficiency	20.48	18.54	6	11150	413	63477453
Eye infection	20.42	18.54	17	11139	12128	63465738
Cutaneous T-cell lymphoma	20.22	18.54	8	11148	1372	63476494
Nasal congestion	20.07	18.54	39	11117	65621	63412245
Pemphigus	19.97	18.54	4	11152	183722	63294144
Stress	19.45	18.54	39	11117	67128	63410738
Therapeutic product effect decreased	19.41	18.54	5	11151	193182	63284684
Fatigue	19.03	18.54	86	11070	887942	62589924
Skin discolouration	18.93	18.54	28	11128	37800	63440066
Anaemia macrocytic	18.63	18.54	10	11146	3444	63474422

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	86.02	19.62	54	3916	38758	34914203
Pruritus	73.02	19.62	85	3885	141896	34811065
Rash	45	19.62	86	3884	222666	34730295
Pain of skin	41.34	19.62	18	3952	6091	34946870
Blister	36.57	19.62	26	3944	22832	34930129
Prurigo	29.51	19.62	8	3962	647	34952314
Inappropriate schedule of product administration	28.13	19.62	35	3935	62261	34890700
Skin candida	26.99	19.62	7	3963	477	34952484
Psoriatic arthropathy	26.00	19.62	20	3950	19778	34933183
Rash erythematous	25.95	19.62	22	3948	24955	34928006
Genital herpes	25.11	19.62	7	3963	628	34952333
Eczema	25.03	19.62	19	3951	18417	34934544
Exercise lack of	23.92	19.62	5	3965	131	34952830
Psoriasis area severity index increased	22.84	19.62	4	3966	39	34952922
Self-consciousness	21.38	19.62	4	3966	58	34952903
Neuropsychiatric syndrome	21.19	19.62	4	3966	61	34952900
Gingival blister	20.31	19.62	4	3966	77	34952884
Enteritis infectious	19.99	19.62	7	3963	1327	34951634
Arthralgia	19.96	19.62	53	3917	169988	34782973
Scratch	19.87	19.62	9	3961	3339	34949622

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriasis	193.29	17.06	144	13630	89443	79641171
Chronic sinusitis	149.32	17.06	63	13711	12963	79717651
Macular degeneration	147.63	17.06	60	13714	11236	79719378
Blepharospasm	146.17	17.06	50	13724	5801	79724813
Paraesthesia oral	133.78	17.06	67	13707	20404	79710210
Procedural pain	115.00	17.06	63	13711	23021	79707593
Taste disorder	104.00	17.06	52	13722	15771	79714843
Pruritus	99.77	17.06	214	13560	394434	79336180
Vaginal flatulence	96.82	17.06	30	13744	2545	79728069
Heart sounds	90.49	17.06	23	13751	943	79729671
Prolonged expiration	84.23	17.06	23	13751	1248	79729366
Epilepsy	75.57	17.06	60	13714	40800	79689814
Female genital tract fistula	75.54	17.06	31	13743	5944	79724670
Proctitis	70.02	17.06	30	13744	6402	79724212
Depressed mood	66.63	17.06	60	13714	48420	79682194
Vaginal discharge	65.74	17.06	30	13744	7433	79723181
Dyspepsia	65.36	17.06	87	13687	108600	79622014
Acute motor-sensory axonal neuropathy	64.74	17.06	15	13759	414	79730200
Radiculopathy	63.95	17.06	31	13743	8793	79721821
Pain	60.70	17.06	261	13513	703541	79027073
Endocrine ophthalmopathy	56.86	17.06	15	13759	713	79729901
Malaise	53.71	17.06	196	13578	489673	79240941
Lip swelling	53.02	17.06	49	13725	40862	79689752
Respiration abnormal	49.42	17.06	25	13749	7763	79722851
Toxic shock syndrome	48.85	17.06	15	13759	1234	79729380
Depressive symptom	47.86	17.06	23	13751	6400	79724214
Oral candidiasis	47.41	17.06	40	13734	29588	79701026
Appetite disorder	46.66	17.06	24	13750	7715	79722899
Blood pressure inadequately controlled	45.66	17.06	22	13752	6155	79724459
Weight decreased	42.19	17.06	146	13628	355052	79375562
Eyelid disorder	42.08	17.06	15	13759	1963	79728651
Skin plaque	41.89	17.06	25	13749	10720	79719894
Gastrooesophageal reflux disease	41.80	17.06	69	13705	104177	79626437
Nasal ulcer	40.93	17.06	15	13759	2125	79728489
Rash pustular	40.70	17.06	25	13749	11286	79719328
Rectal haemorrhage	39.72	17.06	57	13717	76243	79654371
Death	38.93	17.06	25	13749	566489	79164125
Hypotension	38.50	17.06	14	13760	440303	79290311
Therapeutic product effect incomplete	38.18	17.06	79	13695	141566	79589048
Drug interaction	36.64	17.06	13	13761	415170	79315444
Total cholesterol/HDL ratio abnormal	36.19	17.06	7	13767	78	79730536
Swelling of eyelid	35.72	17.06	16	13758	3795	79726819
Eczema	34.80	17.06	39	13735	40779	79689835
Multiple drug therapy	34.68	17.06	16	13758	4062	79726552
Skin exfoliation	34.47	17.06	45	13729	55055	79675559
Mean cell haemoglobin increased	33.93	17.06	16	13758	4269	79726345
Sleep disorder due to a general medical condition	33.09	17.06	24	13750	14253	79716361
Erythema	33.03	17.06	99	13675	223191	79507423
Acute kidney injury	32.92	17.06	25	13749	519379	79211235
Colitis ulcerative	32.75	17.06	35	13739	34707	79695907
Frequent bowel movements	31.88	17.06	32	13742	29507	79701107
Wrong technique in device usage process	31.77	17.06	15	13759	4013	79726601
Steroid withdrawal syndrome	29.65	17.06	9	13765	712	79729902
Skin atrophy	29.56	17.06	16	13758	5702	79724912
Concussion	29.18	17.06	19	13755	9484	79721130
Inappropriate schedule of product administration	28.63	17.06	68	13706	133560	79597054
Pain of skin	28.17	17.06	22	13752	14591	79716023
Exercise tolerance decreased	27.52	17.06	18	13756	9053	79721561
Migraine	27.42	17.06	52	13722	87441	79643173
Abdominal pain upper	27.40	17.06	93	13681	223726	79506888
Skin disorder	26.51	17.06	31	13743	33912	79696702
Vitamin D decreased	26.38	17.06	18	13756	9707	79720907
Flank pain	26.15	17.06	24	13750	19820	79710794
Rash	26.12	17.06	180	13594	578178	79152436
Feeding disorder	26.11	17.06	22	13752	16232	79714382
Rales	25.99	17.06	24	13750	19977	79710637
Dyslipidaemia	25.71	17.06	19	13755	11614	79719000
Vulval cancer stage III	25.65	17.06	4	13770	10	79730604
Weaning failure	25.49	17.06	8	13766	707	79729907
Contusion	24.92	17.06	69	13705	148707	79581907
Angina pectoris	24.54	17.06	37	13737	51695	79678919
Stevens-Johnson syndrome	24.52	17.06	32	13742	39134	79691480
Rash erythematous	24.17	17.06	39	13735	57730	79672884
Paraesthesia	24.03	17.06	76	13698	176247	79554367
Prurigo	23.99	17.06	9	13765	1360	79729254
Pyrexia	23.78	17.06	199	13575	678510	79052104
Haematochezia	23.73	17.06	49	13725	87596	79643018
Blister	23.67	17.06	59	13715	119417	79611197
Colitis	23.50	17.06	44	13730	73263	79657351
Enteritis infectious	22.02	17.06	11	13763	3327	79727287
Plantar fasciitis	21.64	17.06	11	13763	3449	79727165
Synovial cyst	21.26	17.06	16	13758	10049	79720565
Chest discomfort	21.14	17.06	62	13712	137982	79592632
Nasal congestion	20.96	17.06	43	13731	76509	79654105
Eye infection	20.96	17.06	17	13757	11903	79718711
Memory impairment	20.90	17.06	54	13720	111680	79618934
Narrow anterior chamber angle	20.38	17.06	5	13769	177	79730437
Rash macular	20.28	17.06	25	13749	28874	79701740
Drug ineffective	20.09	17.06	279	13495	1080634	78649980
Lipohypertrophy	19.93	17.06	7	13767	877	79729737
Stress	19.81	17.06	43	13731	79569	79651045
Scratch	19.25	17.06	14	13760	8349	79722265
Hepatic function abnormal	18.78	17.06	40	13734	73067	79657547
Diabetes mellitus inadequate control	18.68	17.06	22	13752	24242	79706372
Wound necrosis	17.91	17.06	6	13768	652	79729962
Self-consciousness	17.68	17.06	4	13770	99	79730515
Contraindicated product administered	17.62	17.06	3	13771	157535	79573079
Rheumatoid arthritis	17.57	17.06	7	13767	208463	79522151
Polydipsia	17.38	17.06	12	13762	6593	79724021
Pelvic pain	17.28	17.06	16	13758	13365	79717249
Skin candida	17.16	17.06	8	13766	2079	79728535

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:65023	anti-asthmatic agents
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
MeSH PA	D019141	Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310
Contact dermatitis	indication	40275004	DOID:2773
Seborrheic dermatitis	indication	50563003	DOID:8741
Lichen simplex chronicus	indication	53891004
Granuloma annulare	indication	65508009	DOID:3777
Pruritus ani	indication	90446007
Discoid lupus erythematosus	indication	200938002
Plaque psoriasis	indication	200965009
Scalp psoriasis	indication	238608008
Pruritus of genital organs	indication	267802000
Eruption of skin	indication	271807003	DOID:0050486
Primary cutaneous T-cell lymphoma	indication	400122007
Dermatosis of scalp	indication	402694007	DOID:3136
Telangiectasia disorder	contraindication	247479008
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Pruritus associated with dermatoses	Indication
Dogs	Pruritus associated with dermatoses	Indication
Horses	Inflammatory joint conditions	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Gentocin Otic Solution	Intervet Inc.	2
Topagen Ointment	Intervet Inc.	2
Gentocin Topical Spray	Intervet Inc.	2
Otomax	Intervet Inc.	3
VET BETA-GEN	Med-Pharmex Inc.	2
Betagen Topical Spray	Med-Pharmex Inc.	2
Tri-Otic Ointment	Med-Pharmex Inc.	3
Vetro-Max	Fougera Pharmaceuticals Inc.	3
GBC Ointment	Cronus Pharma Specialities India Private Limited	3
GB Topical Spray	Dechra Veterinary Products LLC	2
Gentamicin Sulfate Topical Spray	First Priority Inc.	2
Gentamicin Topical Spray	Sparhawk Laboratories Inc.	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.24	acidic
pKa2	11.86	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
4018643	VUID
N0000167463	NUI
D01357	KEGG_DRUG
1514	RXNORM
C0750848	UMLSCUI
CHEBI:3077	CHEBI
CHEMBL1497	ChEMBL_ID
D001624	MESH_DESCRIPTOR_UI
9IFA5XM7R2	UNII
16533	PUBCHEM_CID
DB00443	DRUGBANK_ID
10006	MMSL
3225	MMSL
3226	MMSL
4270	MMSL
4278	MMSL
d00628	MMSL
116571008	SNOMEDCT_US
29896003	SNOMEDCT_US
396005002	SNOMEDCT_US
C0005308	UMLSCUI
4018643	VANDF
4018644	VANDF
1045	INN_ID
9782	PUBCHEM_CID
D001623	MESH_DESCRIPTOR_UI
002168	NDDF
002173	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0033	OINTMENT	1 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0040	CREAM	1 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0041	LOTION	1 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8180	AEROSOL, FOAM	1.20 mg	TOPICAL	NDA authorized generic	19 sections
Luxiq	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8187	AEROSOL, FOAM	1.20 mg	TOPICAL	NDA	21 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0370	CREAM	1.20 mg	TOPICAL	ANDA	11 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0371	OINTMENT	1.20 mg	TOPICAL	ANDA	11 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0326	CREAM	1.20 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0326	CREAM	1.20 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0327	OINTMENT	1.20 mg	TOPICAL	ANDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0327	OINTMENT	1.20 mg	TOPICAL	ANDA	18 sections
BETAMETHASONE VALERATE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-034	CREAM	1 mg	TOPICAL	ANDA	12 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-584	CREAM	1 mg	TOPICAL	ANDA	20 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-586	OINTMENT	1 mg	TOPICAL	ANDA	20 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	45802-053	AEROSOL, FOAM	1.20 mg	TOPICAL	ANDA	23 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	45802-053	AEROSOL, FOAM	1.20 mg	TOPICAL	ANDA	23 sections
BETAMETHASONE VALERATE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1647	CREAM	1 mg	TOPICAL	ANDA	20 sections
BETAMETHASONE VALERATE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3134	CREAM	1 mg	TOPICAL	ANDA	21 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3794	CREAM	1.20 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3794	CREAM	1.20 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4696	CREAM	1.20 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4696	CREAM	1.20 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	50742-315	AEROSOL, FOAM	1.20 mg	TOPICAL	ANDA	20 sections
BETAMETHASONE VALERATE	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1269	CREAM	1 mg	TOPICAL	ANDA	21 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4188	AEROSOL, FOAM	1.20 mg	TOPICAL	ANDA	23 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	53002-8450	OINTMENT	1.20 mg	TOPICAL	ANDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9210	CREAM	1 mg	TOPICAL	NDA	18 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9210	CREAM	1 mg	TOPICAL	NDA	18 sections
BETAMETHASONE VALERATE	HUMAN PRESCRIPTION DRUG LABEL	1	53002-9211	CREAM	1 mg	TOPICAL	ANDA	20 sections
Betamethasone Valerate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0520	CREAM	1 mg	TOPICAL	ANDA	19 sections